Interpreting the results of Parkinson's disease clinical trials: Time for a change

Movement Disorders

Volumn 26, Issue 4, 2011, Pages 569-577

  Holford, Nick H G ^a   Nutt, John G ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Clinical trials; Disease modifying therapies; Modeling clinical trials; Parkinson's disease

Indexed keywords

ALPHA TOCOPHEROL; BROMOCRIPTINE; DOPAMINE TRANSPORTER; LEVODOPA; PERGOLIDE; PLACEBO; RASAGILINE; SELEGILINE;

ARTICLE; CLINICAL OBSERVATION; CLINICAL PRACTICE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; HAMILTON SCALE; HUMAN; MATHEMATICAL MODEL; NEUROPROTECTION; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PARKINSON DISEASE; PLACEBO EFFECT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL ANALYSIS; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE;

ANTIPARKINSON AGENTS; HUMANS; LEVODOPA; MODELS, BIOLOGICAL; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79955010405     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23555     Document Type: Article

References (54)

1. The Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.
2. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484-1491.
3. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044-1053.
4. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364-1371.
5. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176-183.
6. The Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61: 561-566.
7. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268-1278.
8. Schulzer M, Mak E, Calne DB. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 1992; 32: 795-798.
9. Schulzer M, Lee CS, Mak EK, Vingerhoets FJ, Calne DB. A mathematical model of pathogenesis in idiopathic parkinsonism. Brain 1994; 117: 509-516.
10. Olanow CW, Kieburtz K, Schapira AH. Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol 2008; 64( Suppl 2): S101-S110.
11. Rascol O. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design. Neurology 2009; 72 ( Suppl 7): S51-S58.
12. Niewoehner DE. TORCH and UPLIFT: what has been learned from the COPD "mega-trials"? COPD 2009; 6( 1): 1-3.
13. Swigris J, Fairclough D. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 36: 695-696.
14. Holford NHG, Peace KE. Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci U S A 1992; 89: 11466-11470.
15. Nutt JG, Chung KA, Holford NHG. Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study. Neurology 2010; 74: 1191-1197.
16. Holford N, Nutt JG. Disease progression, drug action and Parkinson's disease: Why time cannot be ignored. Eur J Clin Pharmacol 2008; 64: 207-216.
17. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996; 39: 561-573.
18. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997; 61: 275-291.
19. Holford NHG, Mould DR, Peck CC. Disease Progress Models. In: Atkinson A, editor. Principles of Clinical Pharmacology. San Diego, CA: Academic Press, 2001. p 253-262.
20. Holford NH, Chan PL, Nutt JG, Kieburtz K, Shoulson I. Disease progression and pharmacodynamics in Parkinson disease-evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn 2006; 33: 281-311.
21. Altman DG, Bland JM. Statistics notes: variables and parameters. BMJ 1999; 318: 1667.
22. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981; 6: 429-453.
23. Chan PLS, Nutt JG, Holford NHG. Modeling the short and long duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease. J Pharmacokinet Pharmacodyn 2004; 31: 243-268.
24. Holford NHG, Peace KE. Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci U S A 1992; 89: 11471-11475.
25. Mould DR, Denman NG, Duffull S. Using disease progression models as a tool to detect drug effect. Clin Pharmacol Ther 2007; 82( 1): 81-86.
26. Sheiner L, Steimer J-L. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 2000; 40: 67-95.
27. Hauser RA, Holford NH. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Mov Disord 2002; 17: 961-968.
28. Bhattaram VA, Siddiqui O, Kapcala LP, Gobburu JV. Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease. AAPS J 2009; 11: 456-464.
29. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002; 51: 604-612.
30. Nutt JG, Carter JH, Lea ES, Sexton GJ. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol 2002; 51: 686-693.
31. Chan PL, Nutt JG, Holford NH. Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease. J Pharmacokinet Pharmacodyn 2005; 32: 459-484.
32. Guimaraes P, Kieburtz K, Goetz CG, et al. Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials 2005; 2: 509-518.
33. Schwartz J, Storch A, Koch W, Pogatell O, Radau PE, Tatsch K. Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than a linear decline. J Nucl Med 2004; 45: 1694-1697.
34. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009; 132( Pt 11): 2970-2979.
35. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992; 32: 804-812.
36. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. Arch Neurol 1999; 56: 529-535.
37. Fahn S. Results of the ELLDOPA (Earlier vs. Later Levodopa) study. Mov Disord 2002; 17( Suppl 5): S13.
38. Chan PLS, Holford NHG, Nutt JG. Application of clinical trial simulation to evaluate the ELLDOPA trial design. Mov Disord 2002; 17: S111-112.
39. Chan PL, Nutt JG, Holford NH. Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation. Pharm Res 2007; 24: 791-802.
40. Leber P. Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord 1996; 10( Suppl 1): 31-35.
41. Holford N, Ma SC, Ploeger BA. Clinical trial simulation: a review. Clin Pharmacol Ther 2010; 88: 166-182.
42. Holford NHG, Peck CC. Population pharmacodynamics and drug development. In: Boxtel CJ, Holford NHG, Danhof M, editors. The In Vivo Study of Drug Action. New York: Elsevier Science Publishers; 1992. p 401-414.
43. Reigner BG, Williams PEO, Patel IH, Steimer JL, Peck C, van Brummelen P. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience with Hoffmann La Roche. Clin Pharmacokinet 1997; 33: 142-152.
44. Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J 2005; 7: E503-E512.
45. Wang Y, Bhattaram AV, Jadhav PR, et al. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. J Clin Pharmacol 2008; 48: 146-156.
46. Manolis E, Pons G. Proposals for model-based paediatric medicinal development within the current European Union regulatory framework. Br J Clin Pharmacol 2009; 68: 493-501.
47. Senn S. Statisticians and pharmacokineticists: what they can still learn from each other. Clin Pharmacol Ther 2010; 88: 328-334.
48. D'Agostino RB, Sr. The Delayed-Start Study Design. N Engl J Med 2009; 361: 1304-1306.
49. Jonsson EN, Sheiner LB. More efficient clinical trials through use of scientific model-based statistical tests. Clin Pharmacol Ther 2002; 72: 603-614.
50. Jadhav PR, Gobburu JVS. Model-based longitudinal data analysis can lead to more efficient drug development: a case study. In: FDA Science Forum 2005, Rockville, MD; 2005. Available at: .
51. Hu C, Sale ME. A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn 2003; 30( 1): 83-103.
52. Mallinckrodt CH, Sanger TM, Dube S, et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry 2003; 53: 754-760.
53. Siddiqui O, Hung HM, O'Neill R. MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat 2009; 19: 227-246.
54. Faries D, Ascher-Svanum H, Belger M. Analysis of treatment effectiveness in longitudinal observational data. J Biopharm Stat 2007; 17: 809-826.